Related references
Note: Only part of the references are listed.Leptin Mediates the Pathogenesis of Severe 2009 Pandemic Influenza A(H1N1) Infection Associated With Cytokine Dysregulation in Mice With Diet-Induced Obesity
Anna J. X. Zhang et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities
Kelvin K. W. To et al.
LANCET INFECTIOUS DISEASES (2013)
Learning from the Messengers: Innate Sensing of Viruses and Cytokine Regulation of Immunity-Clues for Treatments and Vaccines
Jesper Melchjorsen
VIRUSES-BASEL (2013)
Toll-Like Receptor Signaling
Kian-Huat Lim et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe Influenza
Kelvin K. W. To et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults
Joon Young Song et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?
Vincent C. C. Cheng et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection
Nicole Schmitz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Plasmacytoid dendritic cells and Toll-like receptor 7-dependent signalling promote efficient protection of mice against highly virulent influenza A virus
Michael M. Kaminski et al.
JOURNAL OF GENERAL VIROLOGY (2012)
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in Mice
Victoria Jeisy-Scott et al.
JOURNAL OF VIROLOGY (2012)
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Michael T. Osterholm et al.
LANCET INFECTIOUS DISEASES (2012)
Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine
William C. Weldon et al.
PLOS ONE (2012)
Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age
Cynthia Nassim et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Adjuvant solution for pandemic influenza vaccine production
Christopher H. Clegg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain
Ivan F. N. Hung et al.
VACCINE (2012)
Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination
Ivan F. N. Hung et al.
VACCINE (2012)
Therapy of Human Papillomavirus-Related Disease
Peter L. Stern et al.
VACCINE (2012)
Avian influenza A H5N1 virus: a continuous threat to humans
Kelvin K. W. To et al.
EMERGING MICROBES & INFECTIONS (2012)
Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells
Carla Russo et al.
BLOOD (2011)
High Incidence of Severe Influenza among Individuals over 50 Years of Age
Anna J. X. Zhang et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza
Kwok-Hung Chan et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled, trial
P. Noel Barrett et al.
LANCET (2011)
Programming the magnitude and persistence of antibody responses with innate immunity
Sudhir Pai Kasturi et al.
NATURE (2011)
Toll-Like Receptor Agonists Synergize with CD40L to Induce Either Proliferation or Plasma Cell Differentiation of Mouse B Cells
Emmanuelle Boeglin et al.
PLOS ONE (2011)
Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial
Rebecca J. Cox et al.
VACCINE (2011)
Association of Human TLR1 and TLR6 Deficiency with Altered Immune Responses to BCG Vaccination in South African Infants
April Kaur Randhawa et al.
PLOS PATHOGENS (2011)
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists
Deepa Rajagopal et al.
BLOOD (2010)
Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection
Kelvin K. W. To et al.
CLINICAL INFECTIOUS DISEASES (2010)
Prevention of Acute Myocardial Infarction and Stroke among Elderly Persons by Dual Pneumococcal and Influenza Vaccination: A Prospective Cohort Study
Ivan F. N. Hung et al.
CLINICAL INFECTIOUS DISEASES (2010)
Wild Type and Mutant 2009 Pandemic Influenza A (H1N1) Viruses Cause More Severe Disease and Higher Mortality in Pregnant BALB/c Mice
Kwok-Hung Chan et al.
PLOS ONE (2010)
Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod
Caroline Othoro et al.
INFECTION AND IMMUNITY (2009)
Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection
Thomas Welte et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus.
Kathy Hancock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Stacey L. Demento et al.
VACCINE (2009)
Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation
Juliette Mouries et al.
BLOOD (2008)
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus
Bo-Jian Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
Felix Geeraedts et al.
PLOS PATHOGENS (2008)
Imiquimod:: mode of action
M. P. Schoen et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Differential role of TLR- and RLR-signaling in the immune responses to influenza a virus infection and vaccination
Shohei Koyama et al.
JOURNAL OF IMMUNOLOGY (2007)
Influenza vaccine: The challenge of antigenic drift
F. Carrat et al.
VACCINE (2007)
TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses
Alex K. Heer et al.
JOURNAL OF IMMUNOLOGY (2007)
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling
Amanda L. Gavin et al.
SCIENCE (2006)
HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
U Wille-Reece et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Targeting the innate immune response with improved vaccine adjuvants
A Pashine et al.
NATURE MEDICINE (2005)
Recognition of single-stranded RNA viruses by Toll-like receptor 7
JM Lund et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Toll-like receptor control of the adaptive immune responses
A Iwasaki et al.
NATURE IMMUNOLOGY (2004)
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
SJ Gibson et al.
CELLULAR IMMUNOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
MA Tomai et al.
CELLULAR IMMUNOLOGY (2000)
Share Paper
